Advertisement
Advertisement
GYRE
Gyre Therapeutics, Inc. Common Stock
7.28
USDSponsored
-0.02
-0.27%
May 13, 15:59 UTC -4
Closed
Pre-Market
7.26
-0.02
-0.26%
GYRE Earnings Reports
Positive Surprise Ratio
GYRE beat 17 of 35 last estimates.
49%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$27.02M
/-$0.03
Implied change from Q1 26 (Revenue/ EPS)
+19.99%
/-25.00%
Implied change from Q2 25 (Revenue/ EPS)
+0.93%
/-250.00%
Gyre Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, GYRE reported earnings of -0.04 USD per share (EPS) for Q1 26, beating the estimate of -0.07 USD, resulting in a 39.84% surprise. Revenue reached 22.52 million, compared to an expected 32.24 million, with a -30.15% difference. The market reacted with a -12.06% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.03 USD, with revenue projected to reach 27.02 million USD, implying an decrease of -25.00% EPS, and increase of 19.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Gyre Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Gyre Therapeutics, Inc. Common Stock reported EPS of -$0.04, beating estimates by 39.84%, and revenue of $22.52M, -30.15% below expectations.
How did the market react to Gyre Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -12.06%, changed from $8.04 before the earnings release to $7.07 the day after.
When is Gyre Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Gyre Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Gyre Therapeutics, Inc. Common Stock is expected to report EPS of -$0.03 and revenue of $27.02M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement